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Abstract
Background: There is consistent evidence that 50% of patients with acute, steroid-resistant flare
of ulcerative colitis (UC) may achieve remission and avoid colectomy if treated with cyclosporin
(CsA). However, follow-up of the responders has shown that most of them relapse and need
surgery shortly after the response. We compared the records of our CsA-treated patients with
those of other groups in order to help clarify this matter.
Methods: All patients admitted consecutively to our Unit with an attack of UC and treated with
CsA between January 1991 and December 1999 were studied. Patients were begun on
continuously-infused CsA at 2 mg/kg/day (1991–1996), or on NEORAL at an initial dose of 5 mg/
kg/day (1996–1999). The maintenance treatment included oral CsA for 3–6 months with or
without azathioprine (AZA). CsA failure was defined as a relapse requiring steroids with or without
progression to colectomy; the cumulative probability of relapse/colectomy was assessed by Fisher's
exact tests and Kaplan-Meier analysis.
Results: Among the patients, 39/61 (63%) initially responded. These 39 included a fatality and 4
drop-outs (unrelated to the side-effects of CsA), leaving 34 patients for the study. Of these, 61%
and 35% were colectomy-free at 1 and 7 years, respectively; the corresponding figures were 80 and
60% respectively in the subset treated with AZA, but 47% and 15% in the AZA-untreated subgroup
(p= 0.0007 at 7 years). Among the 34 patients, 44% were relapse-free at 1 year, but all had relapsed
at 7 years (p = 0.0635). The overall resort to colectomy was 72%, while 19% of the patients
remained colectomy-free.
Conclusion: Sixty percent of a cohort of patients with steroid-refractory colitis responded to
CsA and 60% of these responders retained the colon after 1 year. These figures fell to 35% at 7
years but improved to 60% on AZA. The overall need for colectomy remains high in these patients
and toxicity must be monitored.
Background
On the basis of the positive experience achieved in con-
trolling organ rejection in the previous decade, the use of
CsA to control acute steroid-refractory flares of UC was
begun in the 1990s [1], when steroid unresponsiveness
constituted a mandatory indication for colectomy in
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~40% of the affected patients [2]. A controlled, albeit
small, study soon showed that CsA can eliminate the need
for immediate colectomy in this context [3], but the long-
term efficacy of the drug in the treatment of UC has not
been clearly established and remains a controversial issue.
Fifteen years after the introduction of CsA to treat refrac-
tory colitis, several authors reviewed their follow-up data
in an attempt to clarify the uncertainties concerning its
long-term effects [4-8]. This study represents a compara-
tive analysis between our results in treating acute steroid-
refractory flares with CsA and the results obtained by oth-
ers.
Methods
Sixty-one patients formed the cohort for this retrospective
study. The Institutional Advisory Board (Comitato Etico
dell'Ospedale San Giovanni Battista della Città di Torino)
approved our intention to extract the data for the study.
Table 1 summarizes the patients' demographics, clinical
features and previous treatments. Between January 1991
and April 1996, a subset of 38 patients were continuously
infused with CsA through a central venous catheter for a
maximum of 14 days; the initial infusion rate of 2 mg/kg/
day was adjusted to maintain the whole blood CsA con-
centration within the upper part of the 60–240 ng/ml
window established during our original kidney transplant
program [9]. Between April 1996 and December 1999, the
second subset of 23 patients received 5 mg/kg/day of the
oral microemulsion formulation NEORAL® for 3 months,
with the same window as guidance. The indication for
intravenous (IV) CsA in the first subset was the persistence
of severe disease (13 ± 3 marks of the Rachmilewitz score
[10]) after at least 1 week of parenteral steroids at 1 mg/kg.
The average daily stool passage in the Neoral subset was 7
± 3, the first hour sedimentation rate was 53 ± 25, and the
hemoglobin concentration was 10 ± 2, yielding a CAI
score of 11 ± 3. As previously shown [11], the frequency
of left-sided disease was the same as that in the IV treated
subset.
Of the initial responders, those responding to Neoral were
immediately placed on maintenance regimes; those
responding to the induction phase with IV CsA were
treated similarly after a 6-month phase of 6–8 mg/kg of
conventional (oral) CsA. The maintenance regimes con-
sisted of therapeutic doses of mesalamine or mesalamine
derivatives, except for 4 cases, of whom one developed a
reduced platelet count when receiving mesalamine. A sub-
set of 15 responders also received AZA at an initial dose of
2 mg/kg, either concurrently with CsA (11 patients) or at
the end of the course (4 cases), as detailed in the Results
section.
Responses and toxicity were monitored as previously
described [11,12]. By the initial response, we intended to
avoid immediate colectomy. Cyclosporin failure was
defined as disease relapse requiring steroids, with or with-
out progression to colectomy.
Statistical analysis
Data were first analyzed by descriptive statistics. Differ-
ences between groups were tested by Student's t-test, chi-
square and Fisher's exact test, as appropriate. The cumula-
tive probability and recurrence of relapse/colectomy was
calculated using the actuarial life table analyses of Kaplan-
Meier, using the log-rank test to compare the curves. Sig-
nificance was assigned if P < 0.05. All the statistical analy-
ses were performed using StatsDirect statistical software
Version 2.5.7.
Results
Sixty-one patients were treated with CsA following an
acute episode of steroid-refractory UC: of these, 39 (63%)
initially responded to CsA. All but 3 patients achieved the
target CsA concentrations; a patient in the IV subset
required her infusion rate to be halved owing to the con-
current use of a synergistic macrolide antibiotic; the
Neoral patients included one high and one poor Neoral
absorber, and the doses for these two patients were halved
or doubled, respectively. The response rate within the
NEORAL-treated subset was 69%. The onset of response
was usually obvious within a week in both subsets and
manifested itself as a reduction in rectal bleeding and a
50% decrease of the entry score. No factor that we could
identify distinguished statistically between the initial
responders and the non-responders (Table 2).
Among the 39 responders, there was one fatality and 4
patients dropped out. The fatality was due to autopsy-
proven pulmonary embolism, which was judged not to be
causally linked to CsA, and the four patients who dropped
out did so for reasons other than CsA toxicity. Among the
remaining 34 responders (Table 3), the overall colectomy-
free rate after 1 year was 61%, 38% after 3 years and 35%
after 7 years. However, the colectomy-free rates dropped
to 47%, 15% and 15%, respectively, at the same time
points in patients without AZA. In AZA-treated patients,
the surgery-free rate was 66% after 3 years and 60% after
7, a statistically significant difference with respect to the
AZA-untreated group (3 years: p = 0.0024; 7 years: p =
0.0007). Of the initial population of 61 patients, 10 sub-
jects (16%) received de-novo AZA; in this subset the
median time to relapse was 26 months and 30% had
colectomy. In a second subset of 7 patients (11%), 5 were
already on AZA prior to treatment with CsA and 2 had
received a single course of AZA prior to treatment with
CsA. In this subset, the median time to relapse was 8
months and 57% underwent colectomy; however, theBMC Gastroenterology 2007, 7:13 http://www.biomedcentral.com/1471-230X/7/13
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small number of these AZA-pretreated patients did not
allow the data to be analyzed statistically.
By Kaplan-Meier analysis, the two curves describing the
AZA-treated and AZA-untreated subsets were time-
dependent (Fig. 1), with the hazard ratio increasing
abruptly from the second year of the follow-up. The
cumulative probability of colectomy differed significantly
between the two curves (p = 0.007). Overall, 44% of the
34 responders were relapse-free after 1 year; however, after
7 years, all had relapsed. After 1 year, the relapse-free rate
was 36% in the AZA-untreated patients, compared with
53% in the AZA-treated patients; after 3 years, the rates
were 10% (- AZA) versus 26% (+ AZA) (p = 0.0635) (Fig.
2). Throughout the CsA course, attempts were made to
reduce the initial steroid doses: of the 30 responders with
available data, 22 were on less than 10 mg of steroids
daily at the end. By the end of the observation period,
72% of the cohort had undergone surgery for UC whereas
19% remained colectomy-free.
The frequencies of serious adverse effects are reported in
Table 4. Tremors, hypertrichosis, and gingival hyperplasia
occurred in 40–60% of patients, mainly in the oral
administration phases.
Discussion
In this retrospective study, we analyzed the immediate
response and the outcome of rescue therapy with CsA in a
cohort of patients whom we treated between 1991 and
1999. The patients included in this study had failed to
respond to a course of full-dose parenteral steroids, and
were therefore diagnosed with refractory UC, with the
attendant threat of colon surgery. The findings are consist-
ent with those from the sources quoted in the Background
and indicate that: (i) the administration of IV or oral CsA
can eliminate the need for immediate colectomy in 60–
80% of patients with steroid-refractory UC; (ii) most of
the responders will relapse with or without progression to
colectomy in the following 3–7 years; (iii) the cumulative
risk for colectomy in initial responders can be signifi-
cantly reduced by the use of AZA as a long-acting mainte-
nance drug. Only the report of Moskowitz is not clearly
consistent with the last point. These authors did not for-
mally conduct a comparative Kaplan-Meier analysis of the
risk for colectomy in the AZA-treated versus the AZA-
untreated subjects in their cohort. Rather, they claimed
that de-novo treated patients were at lower risk for colec-
tomy than those already treated with AZA at the time of
the initial CsA course. The data in our paper are in fact
similar to Moskowitz's findings (see the Results) and we
can probably concur with them in suggesting that the
AZA-pretreated subjects exhibit the poorest response to
CsA in this context. However, the proportion of such
patients in our study was only 11% (31% in Moskowitz's
paper), which precluded stratification by Kaplan-Meier
analysis. This low percentage of "bad responder" patients
may be reflected in our achievement of a higher propor-
tion of colectomy-free patients at the 7th year of follow-up
(35% versus 12%).
It is intriguing that while specialized UC centers like our
own tend to focus on the negative side of their results, pri-
mary care centers highlight the availability of CsA for their
patients and emphasize its effectiveness [13]. The data
may indeed have a positive aspect: (i) if tempted to con-
Table 1: Patients' baseline characteristics
Mean Age (yrs) 34 ± 12
M/F 36/25
Disease Duration (months) 47 ± 7
% disease beyond splenic flexure 63
% Previous ASA use 96
% Previous AZA use 11
% Previous steroid use 100
Table 2: Factors of immediate response to CsA or immediate failure*
Immediate failure Immediate Response
Patients' age at onset (yrs) 31 ± 9 28 ± 11
Age at inclusion (yrs) 36 ± 10 34 ± 12
Disease Duration (months) 57.9 ± 13 51 ± 6
% universal disease 36 28
% transfusion dependent 36 36
% TPN dependent 52 33
White Blood Count (per μλ) 13.9 ± 7.9 × 103 13.0 ± 4.8 × 103
CsA levels (ng/ml whole blood) 251 ± 94 210 ± 37
* None of the differences was statistically significantBMC Gastroenterology 2007, 7:13 http://www.biomedcentral.com/1471-230X/7/13
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sider the action of CsA as limited or short-lived, one
should take into account that all the patients enrolled in
the CsA studies were by definition heading for colectomy;
(ii) the often-emphasized toxicity of CsA can be control-
led when the drug is administered against the background
of an organ-transplant program, and can be further
decreased by low-dosage regimens. The use of low-dose
CsA to treat refractory colitis was originally proposed by
us [14] in an uncontrolled study and later validated inde-
pendently by other authors [7]. Finally, a recent control-
led study has shown that low-dose CsA is as effective as
high-dose [15]. Low-dose treatment might obviously
impact on the toxicity figures. The rates observed in this
work, although not negligible, are lower than those
recorded in other high-dose trials, where for example
infection and renal damage peaked to 20% [16]. The
desirability of low-dose schedules has been similarly
emphasized in recently published therapeutic guidelines
[17], which also suggest that better patient selection and
the use of purine analogues can improve the pharmaco-
logical profile of CsA in its indication for UC.
The novel biological drugs that have been introduced
recently to treat UC have addressed moderately severe
forms of colitis [18,19] and it is felt that their indication
for treating the most severe forms of the disease is prema-
Table 3: Overview of the results achieved in the current cohort study.
All Patients (n = 34) With AZA (n = 15) Without AZA (n = 19)
No colectomy > 1 yr 61a 80 47
No colectomy > 3 yrs 38 66 15
No colectomy > 7 yrs 35 60 15
No relapse > 1 yr 44 53 36
No relapse > 3 yrs 17 26 10
No relapse >7 yrs 0 0 0
a Results are expressed as percentages
Kaplan-Meier curves of the probability of colectomy in patients taking AZA versus no AZA after induction of remission by CsA Figure 1
Kaplan-Meier curves of the probability of colectomy in patients taking AZA versus no AZA after induction of remission by CsABMC Gastroenterology 2007, 7:13 http://www.biomedcentral.com/1471-230X/7/13
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ture [17]. Also, two controlled studies published inde-
pendently have come to opposite conclusions [20,21]; it
may also be noted that in the study with positive findings,
by Järnerot, the patients who fared worse were those with
steroid-refractory disease. Doubts about the effectiveness
of anti-TNF strategies in patients hospitalized with ster-
oid-refractory disease have also been expressed in a
recently published analysis [22].
Conclusion
For patients with severe steroid-refractory UC, a strategy
based on the use of CsA as an inductive therapy is effec-
tive; the progressive occurrence of relapses (eventually fol-
lowed by colectomy) that follows the initial response to
CsA can be significantly reduced (but not abolished) by
the long-term use of a thiopurine drug (AZA); patients
already on AZA will benefit least from this strategy.
Kaplan-Meier curves of the probability of relapse in patients taking AZA versus no AZA after induction of remission by CsA Figure 2
Kaplan-Meier curves of the probability of relapse in patients taking AZA versus no AZA after induction of remission by CsA.
Table 4: Major side effects observed during the intravenous and oral phases of CsA administration
Adverse event Outcome N (%) Treatment Phase
Pulmonary Embolism Death 1 (2.5%) Intravenous
>33% ↑ creatinine Dose maintained 7 (17%) Oral
2 × creatinine Dose reduced 1 (2.5%) Oral
Biliary sludge Drug discontinued 2 (5%) Intravenous
↑ liver function tests Dose maintained 2 (5%) Intravenous
Seizures Dose maintained 1 (2.5%) OralBMC Gastroenterology 2007, 7:13 http://www.biomedcentral.com/1471-230X/7/13
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